MEDANTA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.9
| Stock Code | MEDANTA | Market Cap | 31,469 Cr. | Current Price | 1,170 ₹ | High / Low | 1,456 ₹ |
| Stock P/E | 62.8 | Book Value | 141 ₹ | Dividend Yield | 0.04 % | ROCE | 19.6 % |
| ROE | 15.2 % | Face Value | 2.00 ₹ | DMA 50 | 1,097 ₹ | DMA 200 | 1,162 ₹ |
| Chg in FII Hold | -0.39 % | Chg in DII Hold | 0.77 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 128 Cr. |
| RSI | 64.2 | MACD | 26.2 | Volume | 3,32,979 | Avg Vol 1Wk | 3,92,503 |
| Low price | 955 ₹ | High price | 1,456 ₹ | PEG Ratio | 1.99 | Debt to equity | 0.07 |
| 52w Index | 42.8 % | Qtr Profit Var | -18.4 % | EPS | 17.3 ₹ | Industry PE | 48.0 |
📊 MEDANTA shows a moderately bullish intraday setup. RSI at 64.2 indicates strong momentum but nearing overbought territory, while MACD is positive (26.2), confirming upward bias. Current price is above DMA 50 and DMA 200, reflecting trend strength. However, volume is slightly below the weekly average, which may limit sharp intraday moves.
- 💰 Optimal Buy Price: 1,160–1,170 ₹ (near support zone)
- 📈 Profit-Taking Levels: 1,190 ₹ (first resistance), 1,210 ₹ (next resistance)
- ⚠️ Stop-Loss: 1,150 ₹ (below intraday support)
- ⏳ If Already Holding: Exit near 1,190–1,210 ₹ if RSI crosses 68 or momentum indicators flatten intraday.
Positive
✅ Strong ROCE (19.6%) and ROE (15.2%) highlight efficient capital use.
✅ Price above DMA 50 and DMA 200 confirms technical strength.
✅ DII holdings increased (+0.77%), showing domestic institutional support.
✅ EPS of 17.3 ₹ provides a stable earnings base.
✅ Market cap of 31,469 Cr indicates strong positioning in healthcare sector.
Limitation
⚠️ High P/E (62.8) compared to industry average (48.0) suggests overvaluation.
⚠️ Dividend yield is very low (0.04%), reducing income appeal.
⚠️ PEG ratio of 1.99 indicates expensive valuation relative to growth.
⚠️ Quarterly PAT dropped (107 Cr vs 128 Cr), showing earnings weakness.
⚠️ FII holdings decreased (-0.39%), reflecting reduced foreign investor confidence.
Company Negative News
🚫 Decline in quarterly profits raises concerns about earnings consistency and growth momentum.
Company Positive News
📢 Increased DII holdings highlight domestic investor confidence.
📢 Strong technicals with price above DMA levels support bullish bias.
Industry
🏭 Industry P/E is 48.0, lower than Medanta’s 62.8, suggesting relative overvaluation. Healthcare demand remains strong, supporting long-term growth despite valuation pressures.
Conclusion
🔎 Medanta is a fair candidate for intraday trading today, with bullish momentum supported by technicals. Traders should aim for entries near support and exit around resistance levels, while maintaining strict stop-loss discipline due to high valuation and recent profit decline.